Bhupinder S Mann

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
    Bhupinder S Mann
    Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Clin Cancer Res 13:2318-22. 2007
  2. ncbi FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
    Bhupinder S Mann
    Division of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Rockville, Maryland, USA
    Oncologist 12:1247-52. 2007
  3. ncbi Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen
    Bhupinder S Mann
    Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Clin Cancer Res 11:5671-7. 2005

Detail Information

Publications3

  1. ncbi Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
    Bhupinder S Mann
    Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Clin Cancer Res 13:2318-22. 2007
    ..To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL)...
  2. ncbi FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
    Bhupinder S Mann
    Division of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Rockville, Maryland, USA
    Oncologist 12:1247-52. 2007
    ..Grade 3 or greater chemistry abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine...
  3. ncbi Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen
    Bhupinder S Mann
    Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Clin Cancer Res 11:5671-7. 2005
    ....